STAT+: With $173 million, new startup takes aim at sickle cell
On Tuesday, he announced the founding of new startup Marrow Therapeutics to pursue it, with $173 million in Series A and B funding from Scion Life Sciences, venBio, OrbiMed, and others.
- “We expect it to be as good as [gene therapy] in patients,” Subramanian said, “but to be proven for sure.” Continue to STAT+ to read the full story….
For years, researchers and investors have been searching for a treatment that’s as effective in treating sickle cell disease as gene therapy — but without the many drawbacks.
Biotech entrepreneur Romesh Subramanian thinks he might have one.
How this summary was made: extractive summary — built from the sources' own reporting. It is drawn only from the reporting of the sources listed below — read the originals for full detail. How we summarize →